Owlstone Medical, one of the UK’s most promising medtech start-ups, is continuing its expansion into pharma partnering via a new deal with AstraZeneca.
Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient’s breath has been given a major funding boost.
Breath Biopsy will be tested in its ability to detect several cancers earlier than traditional methods.
Employment has begun of digital health unit engineers.
Tool will help distinguish between those prepared for a colonoscopy and those that aren’t.
Owlstone’s ReCIVA and FAIMS technologies will be used to discover asthma-specific biomarkers.
Trial’s next phase will recruit 3,000 patients across 21 international sites.
